New hope for ALS patients: drug slows disease in Long-Term study
NCT ID NCT00424463
First seen Jan 11, 2026 · Last updated Apr 25, 2026 · Updated 19 times
Summary
This study tested a drug called MCI-186 (edaravone) in 181 people with ALS, a serious nerve disease that weakens muscles. Participants received the drug or a placebo over 24 weeks to see if it could slow the disease's progress. The goal was to measure changes in daily function and safety, offering hope for better management of ALS.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Hospital Organization Miyagi National Hospital
Watari-gun, Miyagi, Japan
Conditions
Explore the condition pages connected to this study.